Management of central nervous system lymphomas using monoclonal antibodies: Challenges and opportunities

Clinical Cancer Research

Volumn 11, Issue 19 II, 2005, Pages

  Wong, Eric T ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA4 INTEGRIN; ANTINEOPLASTIC AGENT; CISPLATIN; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPRATUZUMAB; ETOPOSIDE; GADOLINIUM; HUMAN MONOCLONAL ANTIBODY; IBRITUMOMAB TIUXETAN; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NATALIZUMAB; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PREDNISONE; RITUXIMAB; TEMOZOLOMIDE; TOSITUMOMAB I 131; VINCRISTINE;

ADULT; AGED; ASTHENIA; BONE MARROW SUPPRESSION; BRAIN LYMPHOMA; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG POTENTIATION; FATIGUE; FEVER; HUMAN; INJECTION SITE REACTION; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER TOXICITY; LYMPHOMA; LYMPHOMA CELL; MUCOSA INFLAMMATION; MULTIPLE SCLEROSIS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RIGOR; THROMBOCYTOPENIA;

AGED; ANTIBODIES, MONOCLONAL; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM NEOPLASMS; GADOLINIUM; GLIOMA; HUMANS; IMMUNOTHERAPY; LYMPHOMA; LYMPHOMA, B-CELL; MIDDLE AGED; RADIOIMMUNODETECTION; RADIOIMMUNOTHERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 26444525723     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1004-0002     Document Type: Conference Paper

References (58)

1. O'Neill BP, Illig JJ. Primary central nervous system lymphoma. Mayo Clin Proc 1989;64:1005-20.
2. DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992;10:635-43.
3. Batchelor T, Carson K, O'Neill A, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044-9.
4. DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002;20:4643-8.
5. Blay J-Y, Bouhour D, Carrie C, et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression. J Clin Oncol 1995;86:2922-9.
6. Guha-Thakurta N, Damek D, Pollack C, Hochberg FH. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999;43:259-68.
7. Levitt LJ, Dawson DM, Rosenthal DS, Moloney WC. CNS involvement in non-Hodgkin's lymphoma. Cancer 1980;45:545-52.
8. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin's lymphoma: the risk factors. Hematol Oncol 1990;8:141-5.
9. Scott TF, Hogan EL, Carter TD, Garen PD, Brillman J. Primary intracranial meningeal lymphoma. Am J Med 1990;89:536-8.
10. Lachance DH, O'Neill BP, Macdonald DR, et al. Primary leptomeningeal lymphoma: report of 9 cases, diagnosis with immunocytochemical analysis, and review of the literature. Neurology 1991;41:95-100.
11. Burger PC, Scheithauer BW. Atlas of tumor pathology: tumors of the central nervous system. Washington (DC): Armed Forces Institute of Pathology: 1994. p. 321-7.
12. Hoffman PM, McKelvie P, Hall AJ, Stawell RJ, Santamaria JD. Intraocular lymphoma: a series of 14 patients with clinicopathological features and treatment outcomes. Eye 2003;17:513-21.
13. Zaldivar RA, Martin DF, Holden JT, Grossniklaus HE. Primary intraocular lymphoma: clinical, cytologic, and flow cytometric analysis. Ophthalmology 2004;111: 1762-7.
14. Lachance DH, Louis DN. Case Record of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1995. A 43-year-old man was admitted to the hospital because of increasing leg pain and bladder and bowel incontinence, with confusion. N Engl J Med 1995;333:992-9.
15. Caplan DN, Louis DN. Case record of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30-1996. An 81-year-old, right-handed man was admitted to the hospital because of progressive disorientation and repeated falls. N Engl J Med 1996;335:952-9.
16. Debiais S, Bonnaud I, Cottier JP, et al. A spinal cord intravascular lymphomatosis with exceptionally good outcome. Neurology 2004;63:1329-30.
17. DiGiuseppe JA, Nelson WG, Seifter EJ, Boitnott JK, Mann RB. Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J Clin Oncol 1994;12:2573-9.
18. Wong ET. Correspondence: immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004;101: 2900-2.
19. Danial NN, Pernis A, Rothman PB. Jak-STAT signaling induced by v-abl oncogene. Science 1995;269: 1875-7.
20. Ponzoni M, Arrigoni G, Gould VE, et al. Lack of CD29 (β1 integrin) and CD54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol 2000;31:220-6.
21. Pels H, Montesinos-Rongen M, Schaller C, et al. Clonal evolution as pathogenetic mechanism in relapse of primary CNS lymphoma. Neurology 2004; 63:167-9.
22. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991;9:1580-90.
23. Dahlborg SA, Petrillo A, Crossen JR, et al. The potential for complete and durable response in non-glial primary brain tumors in children and young adults with enhanced chemotherapy delivery. Cancer J Sci Am 1998;4:110-24.
24. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6.
25. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP: an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12:1169-76.
26. Lachance DH, Brizel DM, Gockerman JP, et al. Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology 1994;44: 1721-7.
27. Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of Radiation Therapy Oncology Group Protocol 88-06. J Clin Oncol 1996;14:556-64.
28. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999;94:3294-306.
29. Patte C, Auperin A, Michon J, et al. The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 2001;97:3370-9.
30. Ruffer JE, Glatstein E. Commentary: the blood-brain barrier disruption controversy: does it hold water? Cancer J Sci Am 1998;4:84-5.
31. Wong ET. Neoplastic meningitis. In: Black PM, Loeffler JS, editors. Cancer of the nervous system. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 683-9.
32. Glantz MJ, LaFollette S, Jaeckle KA, et al. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999;17: 3110-6.
33. Blasberg RG, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 1975;195: 73-83.
34. Rubinstein LJ, Herman MM, Long TF, Wilbur JR. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer 1975;35:291-305.
35. Posner JB. Neurologic complications of cancer. Philadelphia: F.A. Davis Company; 1995. p. 282-310.
36. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29:2-9.
37. Raizer JJ, DeAngelis LM, Zelenetz AE, Lauren AE. Activity of rituximab in primary central nervous system lymphoma (PCNSL). Proc Am Soc Clin Oncol 2000; 19:166a.
38. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003;101:466-8.
39. Rubenstein JL, Shen A, Abrey L, et al. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Proc Am Soc Clin Oncol 2004; 22:580s.
40. Angelov L, Vogelbaum MA, Barnett GH, et al. Primary central nervous system lymphoma: response to temozolomide therapy. Neuro-oncol 2003;5:347.
41. Quinn J, Reardon D, Rich J, et al. Phase II treatment of adults with newly diagnosed, progressive, or recurrent primary central nervous system lymphoma with Temodar. Neuro-oncol 2003;5:354.
42. Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004; 101:139-45.
43. Wong E, Barron L, Bloom J, Wu J. Durable responses from immunochemotherapy with rituximab and temozolomide in patients with central nervous system lymphomas. Cancer Biother Radiopharm 2004;19:514.
44. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004;63:901-3.
45. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol 2002;20:3545-57.
46. 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol 2003;30:6-10.
47. Sato S, Miller AS, Inaoki M, et al. CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 1996;5:551-62.
48. Engel P, Nojima Y, Rothstein D, et al. The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocvtes. J Immunol 1993;150:4719-32.
49. Leonard JP, Coleman M, Ketas JC, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051-9.
50. Leonard JP, Coleman M, Ketas JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004;10:5327-34.
51. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
52. Österborg A, Dyer MJS, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. J Clin Oncol 1997;15:1567-74.
53. Rai KR, Freter CE, Mercier RJ, et al. Aletuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891-7.
54. Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman MS. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma 2001;41:77-87.
55. Lundin J, Österborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European study group of CAMPATH-1H treatment in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1998;16:3257-63.
56. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
57. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004;62:2038-43.
58. Terol M-J, López-Guillermo A, Bosch F, et al. Expression of β-integrin adhesion molecules in non-Hodgkin's lymphoma: correlation with clinical and evolutive features. J Clin Oncol 1999;17:1869-75.